Abstract
We previously showed that removal of host-reactive donor T cells from allografts by anti-CD25 immunotoxin (IT) is clinically feasible and reduces the frequency of severe graft-versus-host-disease (GVHD) in a high-risk group of elderly patients undergoing matched-sibling transplantation (
Blood
, 2005
,106
:1123
Disclosures: The work of Stephan Mielke has been supported in part by a grant from the Dr.-Mildered-Scheel Stiftung fuer Krebshilfe, Germany (German Cancer Help).
Author notes
*
Corresponding author
2006, The American Society of Hematology
2006
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal